ELI LILLY & CO (LLY)
US5324571083 - Common Stock
ELI LILLY & CO
NYSE:LLY (7/26/2024, 3:18:28 PM)
After market: 804.74 +0.12 (+0.01%)804.62
-16.57 (-2.02%)
Company Profile
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The company is headquartered in Indianapolis, Indiana and currently employs 43,000 full-time employees. The firm discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its diabetes, obesity and other cardiometabolic products include Basaglar, Humalog, Humulin, Jardiance, Mounjaro, Trulicity and Zepbound. Its oncology products include Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh and Taltz. Its neuroscience products include Cymbalta and Emgality. Its other products and therapies include Cialis and Forteo. The firm manufactures and distributes its products through facilities in the United States (U.S.), including Puerto Rico, and in Europe and Asia. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing, as well as clinical and pre-clinical radioligand therapies in development for the treatment of cancer.
Company Info
ELI LILLY & CO
Lilly Corporate Ctr, Drop Code 1094, Lilly Corporate Ctr
Indianapolis INDIANA 46285
P: 13172762000
CEO: David A. Ricks
Employees: 43000
Website: https://www.lilly.com/
LLY News
4 hours ago - BloombergKnockoff Weight-Loss Drug Dosing May Harm Patients, FDA WarnsUS health regulators warned that patients may be injecting themselves with incorrect amounts of copycat weight-loss drugs, causing harm that has landed some in the hospital.
6 hours ago - Investor's Business DailyStock Market Diverges, With Tesla, Google, ServiceNow, GE In Focus: Weekly ReviewSmall caps continued to lead, while the Nasdaq broke below key levels.
7 hours ago - Investor's Business DailyBiogen Stock Tumbles After European Regulators Unexpectedly Reject Alzheimer's DrugBiogen partner Eisai is planning to ask European regulators to re-examine their decision.
9 hours ago - The Motley FoolPrediction: This Is What Eli Lilly Stock Will Do NextShares of Eli Lilly are up more than 130% in the past year, but this company's moves are far from finished.
22 hours ago - The Motley FoolWhy Weight Loss Drug Developer Stocks Tumbled on ThursdayCompanies like Novo Nordisk and Eli Lilly might soon have a determined competitor in their hottest product category.
22 hours ago - Yahoo FinanceWhy Weight Loss Drug Developer Stocks Tumbled on ThursdayCompanies like Novo Nordisk and Eli Lilly might soon have a determined competitor in their hottest product category.
LLY Twits
Here you can normally see the latest stock twits on LLY, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
